Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Increase (Decrease) in Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Accounts Receivable

AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Accounts Receivable of $6.67 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-05

  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$9.03M, a 178.34% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $15.70M, a 43.66% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$19.10M, a 721.28% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was -$6.16M, a 356.13% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $14.14M.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2024 was -$4.05M.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$994.00K.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in accounts receivable for fiscal 2022 was -$11.30M, a 147.02% decline from fiscal 2021.
Period endIncrease (Decrease) in Accounts Receivable 3 monthIncrease (Decrease) in Accounts Receivable 3 month as first filedIncrease (Decrease) in Accounts Receivable 6 monthIncrease (Decrease) in Accounts Receivable 6 month as first filedIncrease (Decrease) in Accounts Receivable 9 monthIncrease (Decrease) in Accounts Receivable 9 month as first filedIncrease (Decrease) in Accounts Receivable 12 monthIncrease (Decrease) in Accounts Receivable 12 month as first filedIncrease (Decrease) in Accounts Receivable 85 month
2026-06-30-$9.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$6.67M
10-Q · filed 2026-08-05
-$12.43M
derived: sum of 3 quarters · filed 2026-08-05
-$18.59M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$15.70M
10-Q · filed 2026-05-07
-$3.39M
derived: sum of 2 quarters · filed 2026-05-07
-$9.55M
derived: sum of 3 quarters · filed 2026-05-07
$1.97M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31-$19.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$25.26M
derived: sum of 2 quarters · filed 2026-02-26
-$13.73M
derived: sum of 3 quarters · filed 2026-08-05
$14.14M
10-K · filed 2026-02-26
2025-09-30-$6.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$5.37M
derived: sum of 2 quarters · filed 2026-08-05
$33.24M
10-Q · filed 2025-11-10
$36.31M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$11.53M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$39.40M
10-Q · filed 2026-08-05
$42.47M
derived: sum of 3 quarters · filed 2026-08-05
$44.88M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$27.87M
10-Q · filed 2026-05-07
$30.95M
derived: sum of 2 quarters · filed 2026-05-07
$33.35M
derived: sum of 3 quarters · filed 2026-05-07
$36.50M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$3.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$5.48M
derived: sum of 2 quarters · filed 2026-02-26
$8.62M
derived: sum of 3 quarters · filed 2026-02-26
-$4.05M
10-K · filed 2026-02-26
2024-09-30$2.40M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$5.55M
derived: sum of 2 quarters · filed 2025-11-10
-$7.12M
10-Q · filed 2025-11-10
$9.58M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$3.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
-$9.53M
10-Q · filed 2025-08-07
$7.17M
derived: sum of 3 quarters · filed 2026-02-26
$10.19M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31-$12.67M
10-Q · filed 2025-05-08
$4.03M
derived: sum of 2 quarters · filed 2026-02-26
$7.05M
derived: sum of 3 quarters · filed 2026-02-26
$7.89M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$16.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$19.72M
derived: sum of 2 quarters · filed 2026-02-26
$20.56M
derived: sum of 3 quarters · filed 2026-02-26
-$994.00K
10-K · filed 2026-02-26
2023-09-30$3.02M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$3.86M
derived: sum of 2 quarters · filed 2024-11-07
-$17.69M
10-Q · filed 2024-11-07
-$677.00K
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30$841.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$20.71M
10-Q · filed 2024-08-08
-$3.70M
derived: sum of 3 quarters · filed 2024-08-08
-$62.43M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$21.55M
10-Q · filed 2024-05-09
-$21.40M
10-Q · filed 2023-05-08
-$4.54M
derived: sum of 2 quarters · filed 2024-05-09
-$63.27M
derived: sum of 3 quarters · filed 2024-05-09
-$46.63M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31$17.02M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$41.72M
derived: sum of 2 quarters · filed 2024-03-14
-$25.07M
derived: sum of 3 quarters · filed 2024-03-14
-$11.30M
10-K · filed 2024-03-14
-$11.70M
10-K · filed 2023-03-10
2022-09-30-$58.73M
derived: 10-Q 9 month − 10-K/A 6 month · filed 2023-11-08
-$42.09M
derived: sum of 2 quarters · filed 2023-11-08
-$28.31M
10-Q · filed 2023-11-08
-$27.78M
10-Q · filed 2022-11-03
-$27.12M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$16.64M
derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-08-28
$30.42M
10-K/A · filed 2023-08-28
$30.99M
10-Q · filed 2022-08-04
$31.61M
derived: sum of 3 quarters · filed 2023-08-28
$46.30M
derived: sum of 4 quarters · filed 2023-08-28
2022-03-31$13.78M
10-K/A · filed 2023-08-28
$13.71M
10-Q · filed 2022-05-09
$14.97M
derived: sum of 2 quarters · filed 2023-08-28
$29.65M
derived: sum of 3 quarters · filed 2023-08-28
$29.43M
derived: sum of 4 quarters · filed 2023-08-28
2021-12-31$1.19M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
$15.88M
derived: sum of 2 quarters · filed 2023-08-28
$15.65M
derived: sum of 3 quarters · filed 2023-08-28
$24.03M
10-K/A · filed 2023-08-28
$24.02M
10-K · filed 2022-03-01
2021-09-30$14.69M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$14.46M
derived: sum of 2 quarters · filed 2022-11-03
$22.84M
10-Q · filed 2022-11-03
$25.57M
derived: sum of 4 quarters · filed 2023-08-28
2021-06-30-$228.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$8.15M
10-Q · filed 2022-08-04
$10.88M
derived: sum of 3 quarters · filed 2023-08-28
-$3.77M
derived: sum of 4 quarters · filed 2023-08-28
2021-03-31$8.38M
10-Q · filed 2022-05-09
$11.11M
derived: sum of 2 quarters · filed 2023-08-28
-$3.54M
derived: sum of 3 quarters · filed 2023-08-28
-$69.30M
derived: sum of 4 quarters · filed 2023-08-28
2020-12-31$2.73M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
-$11.92M
derived: sum of 2 quarters · filed 2023-08-28
-$77.68M
derived: sum of 3 quarters · filed 2023-08-28
-$11.67M
10-K/A · filed 2023-08-28
-$12.01M
10-K · filed 2021-02-25
2020-09-30-$14.65M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
-$80.41M
derived: sum of 2 quarters · filed 2021-11-04
-$14.40M
10-Q · filed 2021-11-04
-$5.19M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$65.76M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$251.00K
10-Q · filed 2021-08-05
$9.46M
derived: sum of 3 quarters · filed 2022-03-01
$10.23M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$66.01M
10-Q · filed 2021-05-10
$75.22M
derived: sum of 2 quarters · filed 2022-03-01
$75.98M
derived: sum of 3 quarters · filed 2022-03-01
$56.44M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$9.21M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$9.98M
derived: sum of 2 quarters · filed 2022-03-01
-$9.57M
derived: sum of 3 quarters · filed 2022-03-01
$22.20M
10-K · filed 2022-03-01
2019-09-30$766.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$18.78M
derived: sum of 2 quarters · filed 2020-11-05
$12.99M
10-Q · filed 2020-11-05
$13.13M
derived: sum of 4 quarters · filed 2021-02-25
2019-06-30-$19.55M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$12.22M
10-Q · filed 2020-08-10
$12.37M
derived: sum of 3 quarters · filed 2021-02-25
$12.92M
derived: sum of 4 quarters · filed 2021-02-25
2019-03-31$31.77M
10-Q · filed 2020-05-05
$31.91M
derived: sum of 2 quarters · filed 2021-02-25
$32.47M
derived: sum of 3 quarters · filed 2021-02-25
-$3.25M
derived: sum of 4 quarters · filed 2021-02-25
2018-12-31$144.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25
$700.00K
derived: sum of 2 quarters · filed 2021-02-25
-$35.02M
derived: sum of 3 quarters · filed 2021-02-25
-$33.38M
10-K · filed 2021-02-25
2018-09-30$556.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
-$35.16M
derived: sum of 2 quarters · filed 2019-11-12
-$33.53M
10-Q · filed 2019-11-12
$407.00K
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30-$35.72M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
-$34.08M
10-Q · filed 2019-08-08
-$149.00K
derived: sum of 3 quarters · filed 2020-03-12
$132.00K
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$1.64M
10-Q · filed 2019-05-09
$35.57M
derived: sum of 2 quarters · filed 2020-03-12
$35.85M
derived: sum of 3 quarters · filed 2020-03-12
$35.85M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31$33.94M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$34.22M
derived: sum of 2 quarters · filed 2020-03-12
$34.22M
derived: sum of 3 quarters · filed 2020-03-12
$393.00K
10-K · filed 2020-03-12
2017-09-30$281.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$281.00K
derived: sum of 2 quarters · filed 2018-11-08
-$33.54M
10-Q · filed 2018-11-08
2017-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08
-$33.82M
10-Q · filed 2018-08-08
2017-03-31-$33.82M
10-Q · filed 2018-05-09
2016-12-31$33.82M
10-K · filed 2019-03-26
2015-09-30-$34.00K
10-Q · filed 2015-11-09
2015-03-31$26.00K
10-Q · filed 2015-05-11
$17.00K
derived: sum of 2 quarters · filed 2015-05-11
-$40.00K
derived: sum of 3 quarters · filed 2015-11-09
-$45.00K
derived: sum of 4 quarters · filed 2015-11-09
2014-12-31-$9.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-04
-$66.00K
derived: sum of 2 quarters · filed 2015-11-09
-$71.00K
derived: sum of 3 quarters · filed 2015-11-09
-$87.00K
10-K · filed 2015-03-04
2014-09-30-$57.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09
-$62.00K
derived: sum of 2 quarters · filed 2015-11-09
-$78.00K
10-Q · filed 2015-11-09
-$108.00K
derived: sum of 4 quarters · filed 2015-11-09
2014-06-30-$5.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-11
-$21.00K
10-Q · filed 2015-08-11
-$21.39K
10-Q · filed 2014-08-11
-$51.00K
derived: sum of 3 quarters · filed 2015-08-11
-$95.90K
derived: sum of 4 quarters · filed 2015-08-11
2014-03-31-$16.00K
10-Q · filed 2015-05-11
-$15.94K
10-Q · filed 2014-05-12
-$46.00K
derived: sum of 2 quarters · filed 2015-05-11
-$90.90K
derived: sum of 3 quarters · filed 2015-05-11
$20.17K
derived: sum of 4 quarters · filed 2015-05-11
$119.39K
10-Q · filed 2014-05-12
2013-12-31-$30.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-04
-$74.90K
derived: sum of 2 quarters · filed 2015-03-04
$36.17K
derived: sum of 3 quarters · filed 2015-03-04
$50.00K
10-K · filed 2015-03-04
2013-09-30-$44.90K
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10
$66.17K
derived: sum of 2 quarters · filed 2014-11-10
$80.00K
10-Q · filed 2014-11-10
2013-06-30$111.07K
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11
$124.90K
10-Q · filed 2014-08-11
2013-03-31$13.83K
10-Q · filed 2014-05-12
2012-12-31$4.00K
10-K · filed 2015-03-04

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33